jak  (MedChemExpress)

Journal: Aging Cell

Article Title: Senolytic‐Resistant Senescent Cells Have a Distinct SASP Profile and Functional Impact: The Path to Developing Senosensitizers

doi: 10.1111/acel.70358

Figure Lengend Snippet: The SASP impacts extent of SC clearance by senolytics. (A) TUNEL‐positive nuclei as a percent of total cells and (B) representative images of surviving (crystal violet + ) senescent preadipocytes and quantification relative to vehicle‐treated cells after exposure to vehicle or Ruxolitinib (1 μM), which attenuates the pro‐inflammatory SASP, for 3 days followed by Dasatinib 800 nM for 24 h. (C) TUNEL‐positive nuclei as a percent of total cells and (D) survival of SCs pre‐treated with 10 μg/mL LPS for 3 days followed by treatment with Dasatinib 800 nM for 24 h. Quantification of images ( N = 5) is shown on the right. Data are shown as means +/− SEM; 1‐way ANOVA; and post hoc comparisons with by Tukey's HSD multiple comparison (A, C), and are expressed as a function of vehicle‐treated cells; means +/− SEM; paired, 2‐tailed Student's t ‐tests.

Article Snippet: The JAK inhibitor Ruxolitinib (tlrl‐rux) was purchased from InvivoGen (Sigma, St. Louis, MO, USA).

Techniques: TUNEL Assay, Comparison